Prestige Biologics Co., Ltd.

As of March 31, 2026, Prestige Biologics Co., Ltd. carries a market capitalization of 187.00B, placing it among publicly traded companies globally. Its enterprise value stands at 271.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Prestige Biologics Co., Ltd. has 77.75M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 10.37, and the price-to-book ratio stands at 1.74.

These figures are as of March 31, 2026. The EV/Sales ratio of 15.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 271.42B versus a market cap of 187.00B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Prestige Biologics Co., Ltd. maintains a current ratio of 0.25, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.05, indicating elevated leverage, while an interest coverage ratio of -4.29 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Prestige Biologics Co., Ltd. posted a negative return on equity (ROE) of -29.36, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.98, reflecting losses generated across the asset base. The company generates approximately 64.62M in revenue per employee across its workforce of 279.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.41 indicates how many times Prestige Biologics Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Prestige Biologics Co., Ltd.'s stock has declined approximately 58.35% over the past 52 weeks. The 50-day moving average sits at 1,569.42, while the 200-day moving average is 2,167.35.

Over the twelve months ended March 31, 2026, Prestige Biologics Co., Ltd. generated 18.03B in revenue and converted that into -35.42B in net income, yielding earnings per share of -455.61. EBITDA reached -28.62B, while operating income came in at -43.85B.

As of March 31, 2026, Prestige Biologics Co., Ltd. holds 664.67M in cash and equivalents against 85.09B in total debt, resulting in a net debt position of 84.40B. Total book value stands at 107.64B, with working capital of -101.51B providing operational flexibility.

Prestige Biologics Co., Ltd. produced 8.14B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -7.97B in capital expenditures, free cash flow totaled 173.48M - equivalent to 2.23 per share.

Over the twelve months ended March 31, 2026, Prestige Biologics Co., Ltd. posted a gross margin of -104.10, reflecting its pricing power and cost economics. The operating margin of -243.25 and net profit margin of -196.49 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 0.09, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Prestige Biologics Co., Ltd. shareholders.

As of March 31, 2026, Prestige Biologics Co., Ltd. has an Altman Z-Score of -1.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.